Since 2020, Quantify Research has been a proud partner to the European Medicines Agency coordinated ENCePP (European NEtwork for Centers of Pharmacoepidemiology and Pharmacovigilance) initiative.
This network brings together expertise and resources in pharmacoepidemiology and pharmacovigilance across Europe with […]
Using 10 years of national surveillance data from four Nordic countries, Quantify Research in collaboration with Pfizer found that a substantial amount of vaccine-preventable invasive pneumococcal disease remains present in elderly populations, despite the inclusion of pneumococcal conjugate […]
That’s a possible conclusion to draw from Sweden’s HTA body The Dental and Pharmaceutical Benefits Agency, TLV‘s report published this week, on the topic of improving access to drugs for rare diseases.https://www.linkedin.com/company/tlv-the-dental-and-pharmaceutical-benefits-agency/
The pharmaceutical market has shifted in […]
In our latest publication in the Journal of Medical Economics, the cost-effectiveness of bimekizumab was assessed for the treatment of psoriatic arthritis in Sweden in collaboration with UCB and others.
According to Quantify Research co-author and payer expert Linnea […]
? On Friday last week, Quantify Research held its annual fall kick-off in the beautiful city of #Stockholm! Full of energy and inspiration, we connected not only as colleagues, but as a vibrant, unified team celebrating many recent […]
The Quantify Research team can’t wait to see you at #ISPOREurope in #Copenhagen!
We are so excited to welcome all attendees to one of our home cities.
We will be […]
Don’t miss it!
On October 4th and 5th, Quantify Research’s CEO Kirk Geale and Lead Analyst Alexander Rieem Dun will be instructing the ISPOR—The Professional Society for […]
Hopes are high for the first disease modifying treatments in Alzheimer’s disease to be approved on the European market, but many challenges remain. Quantify Research colleagues Anders Gustavsson and Lena Jacobs are […]
The natural history of severe asthma is complex and poorly understood, and until recently we were unable to effectively predict the progression of the disease. To shed light on this important area, we are delighted to share our latest study […]
Extensive article today in the Swedish newspaper Dagens Nyheter on the increasing burden of fatty liver disease (NAFLD), including an interview with Associate Professor Hannes Hagström, co-creater of the HERALD liver data platform together with Quantify Researchs Emilie […]
